Latest Oncology News

TAS-102 Plus Bevacizumab Misses PFS End Point in Frontline Unresectable Metastatic CRC

TAS-102 Plus Bevacizumab Misses PFS End Point in Frontline Unresectable Metastatic CRC

October 22nd 2021

Kristi Rosa

The frontline combination of trifluridine/tipiracil and bevacizumab was not found to result in a significant improvement in progression-free survival over capecitabine and bevacizumab in patients with unresectable metastatic colorectal cancer who are not eligible to receive intensive therapy, missing the primary end point of the phase 3 SOLSTICE trial.

Pembrolizumab/Chemo Approved in Europe for Select Locally Recurrent Unresectable or Metastatic TNBC

Pembrolizumab/Chemo Approved in Europe for Select Locally Recurrent Unresectable or Metastatic TNBC

October 22nd 2021

Kristi Rosa

The European Commission has approved pembrolizumab plus chemotherapy for the frontline treatment of patients with locally recurrent unresectable or metastatic triple-negative breast cancer whose tumors have a PD-L1 expression combined positive score of 10 or higher and who have not previously received chemotherapy for metastatic disease.

FDA Approves Companion Diagnostic for Adjuvant Atezolizumab in Stage II to IIIA NSCLC

FDA Approves Companion Diagnostic for Adjuvant Atezolizumab in Stage II to IIIA NSCLC

October 22nd 2021

Kristi Rosa

The FDA has approved the VENTANA PD-L1 assay to assist in identifying which adult patients with stage II to IIIA non–small cell lung cancer whose tumors have PD-L1 expression on 1% or more of tumor cells are eligible to receive adjuvant atezolizumab following surgery and platinum-based chemotherapy.

Tissue Mapping Center for Cellular Senescence Launched at Yale Cancer Center to Study Human Lymphoid Organs

Tissue Mapping Center for Cellular Senescence Launched at Yale Cancer Center to Study Human Lymphoid Organs

October 22nd 2021

The National Institutes of Health has awarded a grant to fund cellular senescence research in lymphoid organs at Yale Cancer Center.

Will Slow and Steady Progress in Treating SCLC Win the Race?

Will Slow and Steady Progress in Treating SCLC Win the Race?

October 22nd 2021

Christina T. Loguidice

Clinical advances in treatment of small cell lung cancer have lagged behind those of other tumor types, but the delay is not for lack of effort.

Latest Oncology Videos

All Oncology News

Key Advances Showcase the Potential of Precision Medicine in NSCLC

October 5th 2021

Caroline Seymour

The sustainability of next-generation sequencing will be dependent on the implementation of thorough informatics and infrastructure that can support the integration of genomic results into electronic medical records.

Florida Cancer Specialists & Research Institute Leaders Serve on Faculty for Value-Based Cancer Care Summit

October 5th 2021

Senior leaders of Florida Cancer Specialists & Research Institute have been invited to serve on the faculty for the Association for Value-Based Cancer Care 2021 Summit & Educational Program being held in New York, NY on Oct. 13 – 15.

FDA Grants Breakthrough Therapy Designation to Repotrectinib for NTRK+ TKI-Pretreated Advanced Solid Tumors

October 5th 2021

Kristi Rosa

The FDA has granted a breakthrough therapy designation to repotrectinib as a potential therapeutic option for patients with advanced solid tumors that harbor an NTRK gene fusion who have progressed after treatment with 1 or 2 prior TRK TKIs, with or without prior chemotherapy, and who have no satisfactory alternative options.

Monk Reviews Transformative KEYNOTE-826 Data in Cervical Cancer and Next Steps for Research

October 5th 2021

Maggie Tibbitt

Bradley J. Monk, MD, FACS, FACOG, discusses the practice-changing data from KEYNOTE-826 examining pembrolizumab plus chemotherapy with or without bevacizumab and next steps for research in recurrent or metastatic cervical cancer.

Sacituzumab Govitecan Significantly Improves HRQoL Vs Physician’s Choice in mTNBC

October 5th 2021

Courtney Marabella

Sacituzumab govitecan-hziy resulted in a statistically significant and clinically meaningful improvement in health-related quality of life compared with single-agent chemotherapy of physician’s choice in patients with metastatic triple-negative breast cancer.

Enfortumab Vedotin Challenges Standard of Care in Urothelial Carcinoma

October 5th 2021

OncLive Staff

Two indications have been granted by the FDA to the Nectin-4directed antibody, enfortumab vedotin-ejfv, marking a shift in the treatment landscape for patients with advanced urothelial carcinoma.

Amivantamab Plus Lazertinib Demonstrates Activity After Osimertinib and/or Chemo in EGFR-Mutant NSCLC

October 5th 2021

Jessica Hergert

Amivantamab-vmjw in combination with lazertinib demonstrated significant clinical activity with durable responses in patients with EGFR-mutated non–small cell lung cancer who had progressed on osimertinib.

Dr. Nassif on the Efficacy of Early-Phase Clinical Trials in Soft Tissue Sarcoma

October 4th 2021

Elise Nassif, MD

Elise Nassif, MD, discusses the efficacy of early-phase clinical trials in soft tissue sarcoma.

Dr. Rimawi on Mitigating Interstitial Lung Disease in HER2+ Breast Cancer

October 4th 2021

Mothaffar F. Rimawi, MD

Mothaffar Fahed Rimawi, MD, discusses mitigating interstitial lung disease/pneumonitis in HER2-positive breast cancer.

Dr. Hamilton on the Potential Integration of Novel SERDs in ER+/HER2- Breast Cancer

October 4th 2021

Erika P. Hamilton, MD

Erika P. Hamilton, MD, discusses the potential integration of novel selective estrogen receptor degraders into the treatment armamentarium for ER-positive, HER2-negative breast cancer.

Dr. Vose on the Use of CAR T-Cell Therapy in Non-Hodgkin Lymphoma

October 4th 2021

Julie M. Vose, MD

Julie M. Vose, MD, MBA, discusses the use of CAR T-cell therapy in non-Hodgkin lymphoma.

Dr. Salani on the Rationale for Immunotherapy/PARP Inhibitor Combos in Ovarian Cancer

October 4th 2021

Ritu Salani, MD

Ritu Salani, MD, MBA, discusses the rationale for combinations of immunotherapy and PARP inhibitors in ovarian cancer.

Treatment Should Not Be Dependent on Age in Soft Tissue Sarcoma

October 4th 2021

Caroline Seymour

Soft tissue sarcoma was the primary cause of death in patients over the age of 75 years, indicating that age alone should not be a prohibitive factor for treatment in older patients, according to findings from a retrospective analysis that was presented at the 2021 ESMO Congress.

Dr. Yardley on the Role of Ribociclib/Letrozole in HR+ Advanced Breast Cancer

October 4th 2021

Denise A. Yardley, MD

Denise A. Yardley, MD, discusses the efficacy achieved with ribociclib plus letrozole in patients with hormone receptor–positive, HER2-negative advanced breast cancer.

Dr. Thomas on Potential Biomarkers of Response to Berzosertib/Topotecan in SCLC

October 4th 2021

Anish Thomas, MD

Anish Thomas, MD, discusses potential biomarkers of response to the combination of berzosertib plus topotecan in patients with relapsed, platinum-resistant small cell lung cancer.

See All News